Estoril, Portugal–
In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize.
The International CML Foundation awarded our CEO Pat Garcia-Gonzalez with the inaugural ERSAP (Emerging Region Support and Partnership) Prize at the 17th annual John Goldman CML Conference co-sponsored by the iCMLf and the European School of Haematology. The iCMLf Directors and Scientific Advisors selected Pat because of her continued commitment, and The Max Foundation’s aim, to help people face cancer with dignity and hope.
Tim Hughes, iCMLf Chair, stated, “Pat strongly believes that people living with CML have the right to access the best possible treatment and support, wherever they live. This is why she has been so determined to make new drugs for CML fully available to patients in emerging economic regions through access programs, education and global advocacy efforts.”
“I am honored to receive the first ever ERSAP Prize and thank our partners at the International CML Foundation for their recognition.” Pat stated. “I take this award as an opportunity to reflect on how providing access to life-saving treatments to people around the world makes our global community stronger and a more just place to live. There are still so many people around the world who deserve our advocacy and support and we carry out our work on their behalf. This award reignites our commitment for finding innovative solutions to help people face cancer with dignity and hope.”
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
We’re pleased to share that the New England Journal of Medicine has published our “Letter to the Editor” on treatment-free remission for chronic myeloid leukemia in low- and middle-income countries! It was written in collaboration with Dr. Jerry Radich from the Fred Hutchinson Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El….
Watch The Max Foundation’s video from Max Global Experience Uganda. The Max Global Experience Uganda was a fundraising and engagement opportunity for patient leaders, industry partners, and Max team members to come together to expand access to cancer treatment in Africa. The global experience included an all-day symposium, a visit to the Uganda Cancer Institute, and a “last mile” walk along the Nile in solidarity with patients across Africa.
At the 13th Annual SOHO Meeting in Houston (Sept 3–6, 2025), Andrielle Yost, Associate Director of Public Sector Engagement at The Max Foundation, discusses the work the organization is doing to improve access to chronic lymphocytic leukemia (CLL) treatment for patients in low- and middle-income countries (LMICs). Watch the interview here. You can also watch….
